These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 24325739)
1. Side population cell fractions from hepatocellular carcinoma cell lines increased with tumor dedifferentiation, but lack characteristic features of cancer stem cells. Nakayama M; Ogasawara S; Akiba J; Ueda K; Koura K; Todoroki K; Kinoshita H; Yano H J Gastroenterol Hepatol; 2014 May; 29(5):1092-101. PubMed ID: 24325739 [TBL] [Abstract][Full Text] [Related]
2. Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib. Yamada T; Abei M; Danjoh I; Shirota R; Yamashita T; Hyodo I; Nakamura Y BMC Cancer; 2015 Apr; 15():260. PubMed ID: 25885470 [TBL] [Abstract][Full Text] [Related]
3. Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells. Yano H; Iemura A; Fukuda K; Mizoguchi A; Haramaki M; Kojiro M Hepatology; 1993 Aug; 18(2):320-7. PubMed ID: 8393423 [TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Ma S; Chan KW; Hu L; Lee TK; Wo JY; Ng IO; Zheng BJ; Guan XY Gastroenterology; 2007 Jun; 132(7):2542-56. PubMed ID: 17570225 [TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. Guo Z; Li LQ; Jiang JH; Ou C; Zeng LX; Xiang BD World J Gastroenterol; 2014 Feb; 20(8):2098-106. PubMed ID: 24616575 [TBL] [Abstract][Full Text] [Related]
6. Identification of Endothelin-1 and NR4A2 as CD133-regulated genes in colon cancer cells. Puglisi MA; Barba M; Corbi M; Errico MF; Giorda E; Saulnier N; Boninsegna A; Piscaglia AC; Carsetti R; Cittadini A; Gasbarrini A; Sgambato A J Pathol; 2011 Oct; 225(2):305-14. PubMed ID: 21826669 [TBL] [Abstract][Full Text] [Related]
7. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979 [TBL] [Abstract][Full Text] [Related]
8. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression. Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848 [TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data. Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019 [TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077 [TBL] [Abstract][Full Text] [Related]
11. [Progress and prospects in cancer stem cell research for hepatocellular carcinoma]. Xu W; Cao L; Yin ZF Ai Zheng; 2009 Sep; 28(9):1004-8. PubMed ID: 19728923 [TBL] [Abstract][Full Text] [Related]
12. Biology and clinical implications of CD133(+) liver cancer stem cells. Ma S Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864 [TBL] [Abstract][Full Text] [Related]
13. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269 [TBL] [Abstract][Full Text] [Related]
14. Stemness characteristics of fibrolamellar hepatocellular carcinoma: immunohistochemical analysis with comparisons to conventional hepatocellular carcinoma. Zenali MJ; Tan D; Li W; Dhingra S; Brown RE Ann Clin Lab Sci; 2010; 40(2):126-34. PubMed ID: 20421623 [TBL] [Abstract][Full Text] [Related]
15. Investigation of diagnostic utility and expression profiles of stem cell markers (CD133 and CD90) in hepatocellular carcinoma, small cell dysplasia, and cirrhosis. Yilmaz G; Akyol G; Cakir A; Ilhan M Pathol Res Pract; 2014 Jul; 210(7):419-25. PubMed ID: 24702884 [TBL] [Abstract][Full Text] [Related]
16. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells. Jia Q; Zhang X; Deng T; Gao J Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193 [TBL] [Abstract][Full Text] [Related]
17. Identification of cancer stem cells from hepatocellular carcinoma cell lines and their related microRNAs. Xu Y; Xie Y; Wang X; Chen X; Liu Q; Ying M; Zheng Q Oncol Rep; 2013 Nov; 30(5):2056-62. PubMed ID: 24002436 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal. Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214 [TBL] [Abstract][Full Text] [Related]
19. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells. Liu YM; Li XF; Liu H; Wu XL Oncol Rep; 2015 Dec; 34(6):2977-86. PubMed ID: 26370320 [TBL] [Abstract][Full Text] [Related]